Masthead

nCounter® CAR-T Characterization Panel

Masthead

Helping Your Research

The nCounter CAR-T Characterization Panel was created in collaboration with experts in CAR-T therapy to facilitate the development of robust product release assays. Confidently profile CAR-T products for research and manufacturing applications with an automated, and reproducible assay. Ideally suited for new CAR-T development and QC, the CAR-T Characterization Gene Expression Panel can help streamline the CAR-T manufacturing workflow and potentially reduce vein to vein time. This panel can measure eight essential components of CAR-T biology with 780 human genes. 

Empower your knowledge of CAR-T with the most up-to-date biology developed with experts in the field. 

  • Optimize CAR-T method development
  • Create manufacturing acceptance criteria
  • Measure metabolic fitness and persistence
  • Monitor post-infusion exhaustion and toxicity

How It Works

CAR-T Therapy Workflow

Understanding each step of the CAR-T workflow is critical to ensuring quality and efficacy of the final CAR-T product. The nCounter CAR-T Characterization Panel can be used throughout development and manufacturing as a standardized panel of genes for optimizing methods, developing manufacturing acceptance criteria as well as understanding the host influences beyond manufacturing.

In addition to the standard nSolver™ Analysis, genes included in the CAR-T Characterization panel are organized and linked to various advanced analysis modules to allow for efficient exploration of the eight essential aspects of CAR-T biology.

Advanced Analysis Modules Available for CAR-T Characterization

  • Normalization
  • Quality Control
  • Pathway Analysis
  • Cell Profiling
  • Differential Expression
  • Gene Set Analysis
  • Built-in Compatibility for Panel Plus and Protein Analysis

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Partnerships
Specifications
Signatures/ Pathways
TCR Diversity Report
The ROSALIND® Platform
Catalog Information
Partnerships

Partnerships
NanoString is excited to be working with Servier (as project leader), Bayer, Janssen, and Takeda as partners with the Innovative Medicines Initiative (IMI) Consortium in the European Union to develop gold standard analytical methods to use throughout development, manufacturing, and delivery of CAR-T cell therapies. The IMI is the largest public-private partnership in the world dedicated to health research.

Specifications
Signatures/ Pathways
TCR Diversity Report

The TCR Diversity report is available for purchase separately from NanoString for use within the ROSALIND® Platform and evaluates the expression of variable regions of the T cell receptor. The variable regions are assessed for overall expression (above or below background) and normalized to a panel standard which allows for more precise quantification of these variable regions. An estimate of TCR Diversity is calculated and shown relative to designated grouping variables.

The TCR score calculates the diversity of T cell receptor beta variable regions within a sample. The score is based on the Shannon Diversity index calculation, a mathematical measure of species diversity within a community. This ecological calculation accounts for the abundance and evenness of the variable regions present within a given sample versus the population of T cell receptors within a given dataset. A given score is relative within a dataset, and a higher TCR score means there is a more diverse population of variable regions or a less clonal population. A lower TCR score means there is less diversity or a more clonal population. True clonality can only be determined by full sequencing of the T cell receptors, but clonality can be estimated by measuring the diversity of TCR beta variable regions.

The ROSALIND® Platform

ROSALIND is a cloud-based platform that enables scientists to analyze and interpret differential gene expression data without the need for bioinformatics or programming skills.  ROSALIND makes analysis of nCounter data easy, with guided modules for:

  • Normalization
  • Quality Control
  • Individual Pathway Analysis
  • Differential Expression
  • Gene Set Analysis

nCounter customers can access ROSALIND free of charge.

Catalog Information

Related Resources

See All Resouces
Product Bulletin CAR-T Characterization Panel – Product Bulletin
Blog Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog SITC in Focus: CAR-T Cell Therapy
Poster CAR-T EU Congress 2019 Poster – A Step Toward Standardization with the nCounter® CAR-T Characterization Panel
Blog What is the Next Frontier in Cellular Therapy?

Publications

View All Publications

Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

The adoptive transfer of regulatory T-cells (Tregs) is a promising therapeutic approach in transplantation and autoimmunity. However, because large cell numbers are needed to achieve a therapeutic effect, in vitro expansion is required.

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.

Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss.

A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.

Background aims: Next-generation immune cell therapy products will require complex modifications using engineering technologies that can maintain high levels of cell functionality. Non-viral engineering methods have the potential to address limitations associated with viral vectors.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us